首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Immunomodulatory Effects of Kuseonwangdogo-Based Mixed Herbal Formula Extracts on a Cyclophosphamide-Induced Immunosuppression Mouse Model
【24h】

Immunomodulatory Effects of Kuseonwangdogo-Based Mixed Herbal Formula Extracts on a Cyclophosphamide-Induced Immunosuppression Mouse Model

机译:基于基于Kuseonwangdogo的混合草药提取物对环磷酰胺诱导的免疫抑制小鼠模型的免疫调节作用

获取原文
获取原文并翻译 | 示例
           

摘要

Aim. Kuseonwangdogo is a traditional Korean immunomodulatory polyherbal prescription. However, there are no systemic findings on its complex immunomodulatory effects on in vivo models. In this study, we observed the immunomodulatory effects of Kuseonwangdogo-based mixed herbal formula aqueous extracts (MHFe) on cyclophosphamide-(CPA-)induced immunosuppression mouse model. Methods. In total, 60 male 6-week-old ICR mice (10 mice/group) were selected based on body weight 24 h after the second CPA treatment and used in this experiment. Twelve hours after the end of the last (fourth) oral administration of MHFe, the animals were sacrificed. Results. Following CPA treatment, a noticeable decrease in the body, thymus, spleen, and submandibular lymph node (LN) weights; white blood cell, red blood cell, platelet number, hemoglobin, and hematocrit concentrations; serum interferon-gamma levels; splenic tumor necrosis factor-alpha, interleukin- (IL-) 1 beta, and IL-10 content; and peritoneal and splenic natural killer cell activities was observed. Depletion of lymphoid cells in the thymic cortex, splenic white pulp, and submandibular LN-related atrophic changes were also observed. However, these CPA-induced myelosuppressive signs were markedly and dose-dependently inhibited by the oral administration of 125, 250, and 500mg/kg MHFe. Conclusion. MHFe can be a promising, potent immunomodulatory therapeutic agent for various immune disorders.
机译:目的。 Kuseonwangdogo是一种传统的韩国免疫调节聚类药物处方。然而,对体内模型的复杂免疫调节作用没有全身发现。在这项研究中,我们观察到基于Kuseonwangdogo的混合草本含水提取物(MHFE)对环磷酰胺(CPA)诱导的免疫抑制小鼠模型的免疫调节作用。方法。总共60只男性6周龄ICR小鼠(10只小鼠/组),在第二次CPA处理后24小时选择,并在该实验中使用。在最后一次(第四)口服MHFE的口服局结束后12小时,处死动物。结果。在CPA治疗之后,体内,胸腺,脾脏和颌下淋巴结(LN)重量的显着减少;白细胞,红细胞,血小板数,血红蛋白和血细胞比容浓度;血清干扰素-γ水平;脾脏肿瘤坏死因子-α,白细胞介素 - (IL-)1β和IL-10含量;观察到腹膜和脾脏自然杀手细胞活性。还观察到胸腺皮质,脾脏白纸浆和颌骨凋亡相关萎缩变化的淋巴细胞枯竭。然而,这些CPA诱导的髓抑制症状被125,250和500mg / kg MHFE的口服给药依赖性和剂量依赖性抑制。结论。 MHFE可以是各种免疫疾病的有希望的强大免疫调节治疗剂。

著录项

  • 来源
  • 作者单位

    Aribio Co Ltd 2-301 Pangyo Seven Venture Valley Sungnam 13487 Gyeonggi Do South Korea;

    Silla Univ Coll Med &

    Life Sci Div Bioind 140 Baegyang Daero 700 Beon Gil Busan 46958 South;

    Aribio Co Ltd 2-301 Pangyo Seven Venture Valley Sungnam 13487 Gyeonggi Do South Korea;

    Aribio Co Ltd 2-301 Pangyo Seven Venture Valley Sungnam 13487 Gyeonggi Do South Korea;

    Daegu Haany Univ Coll Korean Med Dept Anat &

    Histol Gyongsan 38610 Gyeongsangbuk D South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 临床医学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号